Page 6 - Bio Path News Today

Bio-Path (NASDAQ:BPTH – Get Rating) and Chinook Therapeutics (NASDAQ:KDNY – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a summary of current ratings and […]

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Get Rating) in a research note issued to investors on Tuesday. The firm issued a sell rating on the stock. Separately, Roth Capital reiterated a buy rating on shares of Bio-Path in a report on Friday, March 17th. Bio-Path Trading Down 1.7 % Shares of BPTH […]

StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Get Rating) in a research note released on Tuesday. The firm issued a sell rating on the stock. Separately, Roth Capital reaffirmed a buy rating on shares of Bio-Path in a report on Friday, March 17th. Bio-Path Trading Up 2.3 % Shares of BPTH stock opened […]

Wall Street brokerages expect Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Rating) to report earnings per share of ($0.50) for the current quarter, according to Zacks. Zero analysts have made estimates for Bio-Path’s earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.52). Bio-Path posted earnings of ($0.26) per share in the same quarter […]

StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH – Get Rating) in a research report issued on Saturday. The firm set a “sell” rating on the stock. A number of other analysts have also recently commented on BPTH. Zacks Investment Research cut shares of Bio-Path from a “hold” rating to a “sell” rating in a […]

Bio-Path (NASDAQ:BPTH – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday, Zacks.com reports. According to Zacks, “BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug […]

BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Monday reported a loss of $3.4...

StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH – Get Rating) in a research note issued to investors on Friday. The firm set a “sell” rating on the stock. Separately, Zacks Investment Research lowered Bio-Path from a “hold” rating to a “sell” rating in a research note on Wednesday. NASDAQ:BPTH opened at $2.84 on Friday. […]

Equities research analysts expect Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Rating) to report ($0.46) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Bio-Path’s earnings, with the highest EPS estimate coming in at ($0.39) and the lowest estimate coming in at ($0.52). Bio-Path reported earnings per share of […]

Brokerages expect Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Rating) to announce earnings per share (EPS) of ($0.46) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Bio-Path’s earnings, with estimates ranging from ($0.52) to ($0.39). Bio-Path posted earnings of ($0.43) per share in the same quarter last year, which […]